|
| 38086777 | Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGAD. | Ann Neurol | 2024 |
| 37676297 | Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. | J Neurol | 2024 |
| 36786424 | Cognition in patients with neuromyelitis optica spectrum disorders: A prospective multicentre study of 217 patients (CogniNMO-Study). | Mult Scler | 2023 |
| 36205793 | Somatosensory evoked potentials and magnetic resonance imaging of the central nervous system in early multiple sclerosis. | J Neurol | 2023 |
| 36319190 | Association of obesity with disease outcome in multiple sclerosis. | J Neurol Neurosurg Psychiatry | 2023 |
| 36427289 | Percentage brain volume change in multiple sclerosis mainly reflects white matter and cortical volume. | Ann Clin Transl Neurol | 2023 |
| 36413917 | Real-world operation of multiple sclerosis centres in Central-Eastern European countries covering 107 million inhabitants. | Mult Scler Relat Disord | 2023 |
| 36318271 | Early spinal cord pseudoatrophy in interferon-beta-treated multiple sclerosis. | Eur J Neurol | 2023 |
| 37753809 | A Genetic Risk Variant for Multiple Sclerosis Severity is Associated with Brain Atrophy. | Ann Neurol | 2023 |
| 37821561 | The role of intrathecal free light chains kappa for the detection of autoimmune encephalitis in subacute onset neuropsychiatric syndromes. | | 2023 |
| 38090586 | Association of retinal vessel pathology and brain atrophy in relapsing-remitting multiple sclerosis. | | 2023 |
| 37780055 | Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outline. | | 2023 |
| 37961043 | Benefits of a mosaic approach for assessing cortical atrophy in individual multiple sclerosis patients. | Brain Behav | 2023 |
| 37692259 | Factors associated with depressive mood at the onset of multiple sclerosis - an analysis of 781 patients of the German NationMS cohort. | Ther Adv Neurol Disord | 2023 |
| 37022481 | Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD)Â - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. | J Neurol | 2023 |
| 36635219 | Retinal ganglion cell loss is associated with future disability worsening in early relapsing-remitting multiple sclerosis. | Eur J Neurol | 2023 |
| 36873454 | CNS demyelinating events in primary Sjögren's syndrome: A single-center case series on the clinical phenotype. | Front Neurol | 2023 |
| 36866852 | Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. | Ann Neurol | 2023 |
| 36693760 | Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Diseases: COPANMO(G)-Study. | Neurol Neuroimmunol Neuroinflamm | 2023 |
| 36623350 | Lesion location across diagnostic regions in multiple sclerosis. | Neuroimage Clin | 2023 |
| 36993939 | Retrospective cohort study to devise a treatment decision score predicting adverse 24-month radiological activity in early multiple sclerosis. | Ther Adv Neurol Disord | 2023 |
| 37114235 | A single relapse induces worsening of disability and health-related quality of life in patients with neuromyelitis optica spectrum disorder. | | 2023 |
| 37114068 | The impact of disease-modifying therapies on immunoglobulin blood levels in patients with multiple sclerosis: a retrospective cross-sectional study. | Ther Adv Neurol Disord | 2023 |
| 37294304 | [Ocrelizumab-associated severe neutropenia: an underestimated complication of treatment of multiple sclerosis with anti-CD20 antibodies?] | Nervenarzt | 2023 |
| 37495267 | Prognostic value of spinal cord lesion measures in early relapsing-remitting multiple sclerosis. | J Neurol Neurosurg Psychiatry | 2023 |
| 35082170 | Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody-Associated Disease: CHANCE<sup>NMO</sup> Study. | Neurology | 2022 |
| 35456972 | Adverse Events in NMOSD Therapy. | International Journal of Molecular Sciences | 2022 |
| 35702403 | Chronic Pain and the Endocannabinoid System: Smart Lipids - A Novel Therapeutic Option? | Medical Cannabis and Cannabinoids | 2022 |
| 35490449 | German guideline for diagnosis and treatment of multiple sclerosis - a survey focusing neurologists in daily practise. | Multiple Sclerosis and Related Disorders | 2022 |
| 35473756 | Cerebrospinal fluid lactate levels along the Alzheimer's disease continuum and associations with blood-brain barrier integrity, age, cognition, and biomarkers. | Alzheimer's Research and Therapy | 2022 |
| 36439131 | Association of the retinal vasculature, intrathecal immunity, and disability in multiple sclerosis. | Front Immunol | 2022 |
| 35468568 | Multiple sclerosis lesions and atrophy in the spinal cord: Distribution across vertebral levels and correlation with disability. | Neuroimage Clin | 2022 |
| 34259579 | Optical coherence tomography angiography indicates subclinical retinal disease in neuromyelitis optica spectrum disorders. | Mult Scler | 2022 |
| 35301260 | Dynamics of Retinal Vessel Loss After Acute Optic Neuritis in Patients With Relapsing Multiple Sclerosis. | Neurol Neuroimmunol Neuroinflamm | 2022 |
| 34498507 | Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension. | Multiple Sclerosis Journal | 2022 |
| 34591698 | Gray matter atrophy in relapsing-remitting multiple sclerosis is associated with white matter lesions in connecting fibers. | Mult Scler | 2022 |
| 35057809 | Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients. | Journal of Neuroinflammation | 2022 |
| 31381862 | Assessment of a novel, smartglass-based control device for electrically powered wheelchairs. | Disabil Rehabil Assist Technol | 2021 |
| 32055874 | T1-Weighted Intensity Increase After a Single Administration of a Linear Gadolinium-Based Contrast Agent in Multiple Sclerosis. | Clin Neuroradiol | 2021 |
| 33586143 | Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD. | Annals of Neurology | 2021 |
| 33676197 | Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension. | Multiple Sclerosis and Related Disorders | 2021 |
| 34108267 | Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder: A Cross-Sectional Study of 166 AQP4 Antibody-Seropositive Patients. | Neurol Neuroimmunol Neuroinflamm | 2021 |
| 33777853 | Drug Treatment of Neuromyelitis Optica Spectrum Disorders: Out with the Old, in with the New? | ImmunoTargets and Therapy | 2021 |
| 34262784 | Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients. | Mult Scler J Exp Transl Clin | 2021 |
| 34250938 | Age-Dependency of Total Tau in the Cerebrospinal Fluid Is Corrected by Amyloid-β 1-40: A Correlational Study in Healthy Adults. | Journal of Alzheimer's Disease | 2021 |
| 33310418 | Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial. | Multiple Sclerosis and Related Disorders | 2021 |
| 33171011 | The serotonin receptor 2A (HTR2A) rs6313 variant is associated with higher ongoing pain and signs of central sensitization in neuropathic pain patients. | European Journal of Pain | 2021 |
| 34561843 | Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing-Remitting Multiple Sclerosis. | Neurotherapeutics | 2021 |
| 34445607 | Simultaneous Quantification and Speciation of Trace Metals in Paired Serum and CSF Samples by Size Exclusion Chromatography-Inductively Coupled Plasma-Dynamic Reaction Cell-Mass Spectrometry (SEC-DRC-ICP-MS). | International Journal of Molecular Sciences | 2021 |
| 34362474 | Controversy on the treatment of multiple sclerosis and related disorders: positional statement of the expert panel in charge of the 2021 DGN Guideline on diagnosis and treatment of multiple sclerosis, neuromyelitis optica spectrum diseases and MOG-IgG-associated disorders. | Neurol Res Pract | 2021 |